Margin resik Intellia Therapeutics Inc (NTLA)

Simbol lan logo merek Intellia Therapeutics (NTLA)

Leadership in CRISPR technologies and patent protection support the quotes of Intellia Therapeutics (NTLA), as confirmed by sales margin dynamics. However, the lack of commercial products and reliance on equity offerings create financial volatility. Experienced management is systematically steering development toward approval. The value of -805.80 determines this parameter level, allowing for a comparison of current profitability with historical data to assess the market trend.

Intellia Therapeutics (NTLA) - Margin dodolan resik saka 04.07.2022 nganti 20.11.2026

Rincian analitis perusahaan Intellia Therapeutics

- rega saham lan prakiraan rega para ahli:
Analisis wiwitan perusahaan:Intellia Therapeutics, NTLA
Barang unggulan Intellia Corp

The monopoly status of Intellia Therapeutics (NTLA), secured by CRISPR/Cas9 patents and high FDA regulatory barriers, determines the future profitability of the business. By analyzing the net profit margin, an investor assesses the portion of profit in every dollar of revenue after deducting all operating expenses and taxes. Positive dynamics in this metric confirm the effective capitalization of intellectual property and the real cash return on innovation.

Analisis pesaing Intellia Therapeutics

TEM: Margin dodolan resik|Tingkat bathi miturut bathi resik Qiagen QGEN|IONS (Isis Pharmaceuticals) - Margin dodolan resik|Repligen Inc. - Margin bathi resik|Margin dodolan resik RNA|CRSP - Margin resik|GeneDx - Rentabilitas dodolan miturut bathi resik|Tingkat bathi resik RARE|Beam Tx - Margin dodolan resik|SRPT - Margin dodolan resik|TWST (Twist Bio) - Rentabilitas dodolan miturut bathi resik|Rentabilitas dodolan resik TXG|Margin resik Stoke Therapeutics Inc|BLFS: Tingkat bathi resik|Rentabilitas dodolan miturut bathi resik WVE (Wave Life Sciences Corp)|Margin dodolan perusahaan Maze Therapeutics Corp|Sionna Therapeutics Inc - Rentabilitas dodolan miturut bathi resik|PRME (primemedicine.com) - Margin bathi resik|TSHA - Margin resik|QURE (uniQure) - Rentabilitas dodolan resik|MeiraGTx Corp (MGTX) - Margin resik|Regenxbio - Tingkat bathi resik|Margin resik solidbio.com|Margin resik ocugen.com OCGN|Margin dodolan resik PACB|Benitec - Rentabilitas dodolan resik|Margin resik Design Therapeutics DSGN|Margin dodolan resik Rocket Pharmaceuticals RCKT|Margin bathi resik 4D Molecular Corp|LXEO: Margin resik|KRRO (Korro Bio, Inc) - Rentabilitas dodolan miturut bathi resik|Editas Medicine (EDIT) - Margin dodolan resik|Margin resik Silence Therapeutics Inc.|Rentabilitas dodolan resik PRQR (proqr.com)|Margin resik Codexis Bio (CDXS)|Margin dodolan resik sangamo.com (SGMO)|Margin resik nautilus.bio NAUT|Margin dodolan perusahaan Metagenomi, Inc (MGX)|Precision BioSciences Inc. - Margin dodolan resik|GBIO - Margin dodolan resik|BOLD: Margin dodolan resik|Rentabilitas dodolan resik XCUR|Margin resik Imunon|Phio Pharmaceuticals - Margin bathi resik|Margin resik Mustang Bio, Inc. (MBIO)|Margin dodolan perusahaan TransCode Therapeutics, Inc.|Margin resik Bionano Genomics BNGO|Tingkat bathi resik APDN|BLUE - Margin resik|Margin bathi resik IPA|Omega Therapeutics, Inc. (OMGA) - Margin resik|Singular Genomics Corp (OMIC) - Margin dodolan resik|RGLS (Regulus Therapeutics, Inc.) - Margin dodolan resik|SYRS: Tingkat bathi resik|Rentabilitas dodolan miturut bathi resik TBIO (Telesis Bio Inc.)|Margin dodolan resik TRACON Pharmaceuticals Inc. (TCON)|Margin resik Unity Bio UBX